Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
Aytu BioPharma (NASDAQ:AYTU) has scheduled its fiscal 2025 third quarter operational and financial results announcement for May 14, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time, featuring a results review and Q&A session.
Participants can join via phone using the numbers (888) 506-0062 (US) or +1 (973) 528-0011 (international) with access code 314386. The webcast will be available live and archived at the company's investor relations website. A replay will be accessible until May 28, 2025.
Aytu BioPharma (NASDAQ:AYTU) ha programmato l'annuncio dei risultati operativi e finanziari del terzo trimestre fiscale 2025 per il 14 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call e una webcast lo stesso giorno alle 16:30 ora orientale, con una revisione dei risultati e una sessione di domande e risposte.
I partecipanti possono collegarsi telefonicamente utilizzando i numeri (888) 506-0062 (USA) o +1 (973) 528-0011 (internazionale) con il codice di accesso 314386. La webcast sarà disponibile in diretta e archiviata sul sito web delle relazioni con gli investitori della società. Una replica sarà accessibile fino al 28 maggio 2025.
Aytu BioPharma (NASDAQ:AYTU) ha programado el anuncio de sus resultados operativos y financieros del tercer trimestre fiscal 2025 para el 14 de mayo de 2025, después del cierre del mercado. La compañía realizará una llamada conferencia y una transmisión en vivo el mismo día a las 4:30 p.m. hora del Este, que incluirá una revisión de resultados y una sesión de preguntas y respuestas.
Los participantes pueden unirse por teléfono usando los números (888) 506-0062 (EE. UU.) o +1 (973) 528-0011 (internacional) con el código de acceso 314386. La transmisión en vivo estará disponible en el sitio web de relaciones con inversionistas de la compañía y se archivará. Una repetición estará accesible hasta el 28 de mayo de 2025.
Aytu BioPharma (NASDAQ:AYTU)는 2025 회계연도 3분기 운영 및 재무 실적 발표를 2025년 5월 14일 장 마감 후에 예정하고 있습니다. 회사는 같은 날 동부 시간 오후 4시 30분에 실적 검토 및 질의응답 세션이 포함된 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
참석자는 전화로 (888) 506-0062 (미국) 또는 +1 (973) 528-0011 (국제) 번호를 이용해 액세스 코드 314386으로 참여할 수 있습니다. 웹캐스트는 회사 투자자 관계 웹사이트에서 실시간 및 아카이브로 제공됩니다. 재방송은 2025년 5월 28일까지 이용 가능합니다.
Aytu BioPharma (NASDAQ:AYTU) a programmé l'annonce de ses résultats opérationnels et financiers du troisième trimestre fiscal 2025 pour le 14 mai 2025, après la clôture du marché. La société organisera une conférence téléphonique et un webcast le même jour à 16h30 heure de l'Est, comprenant une revue des résultats et une session de questions-réponses.
Les participants peuvent se joindre par téléphone en utilisant les numéros (888) 506-0062 (États-Unis) ou +1 (973) 528-0011 (international) avec le code d'accès 314386. Le webcast sera disponible en direct et en archive sur le site des relations investisseurs de la société. Une rediffusion sera accessible jusqu'au 28 mai 2025.
Aytu BioPharma (NASDAQ:AYTU) hat die Bekanntgabe der operativen und finanziellen Ergebnisse für das dritte Quartal des Geschäftsjahres 2025 für den 14. Mai 2025 nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten, die eine Ergebnisübersicht sowie eine Fragerunde umfassen.
Teilnehmer können sich telefonisch unter den Nummern (888) 506-0062 (USA) oder +1 (973) 528-0011 (international) mit dem Zugangscode 314386 einwählen. Der Webcast wird live und als Archiv auf der Investor-Relations-Website des Unternehmens verfügbar sein. Eine Wiederholung ist bis zum 28. Mai 2025 zugänglich.
- None.
- None.
DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its third quarter of fiscal 2025, after the market close on Wednesday, May 14, 2025. The Company has scheduled a conference call and webcast that same day, Wednesday, May 14, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Wednesday, May 14, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 314386.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/52282, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until May 28, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 52282.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Aytu BioPharma (AYTU) report its Q3 2025 earnings?
How can I join Aytu BioPharma's Q3 2025 earnings call?
What time is AYTU's Q3 2025 earnings conference call?
How long will the replay of AYTU's Q3 2025 earnings call be available?
